Why Is Gain Therapeutics (GANX) Stock Down 25% Today?

Gain Therapeutics (NASDAQ:GANX) stock is falling on Friday following the pricing of its shares in a public offering. Gain Therapeutics is also offering underwriters the option of acquiring another 1,222,222 shares in this public offering. Titan Partners Group is acting as the sole bookrunner for this offering. With this public offering, Gain Therapeutics is increasing the total number of outstanding shares. Doing so dilutes the stakes of current investors in the biotechnology company. That's one reason why ...